A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

Part of paid clinical trials in Anaheim, California.

Sponsor
AbbVie
Study ID
NCT07413133
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Key Dates

Start date
Feb 11, 2026
Status verified
Apr 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Arm 1: Intravenous (IV) ABBV-8736
    Participants will receive IV ABBV-8736 on Day 1.
  • Experimental: Arm 2: Subcutaneous (SC) ABBV-8736
    Participants will receive SC ABBV-8736 on Day 1.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to At Least 3 Months ]

Locations (2)

FacilityCityStateZIPSite coordinators
CenExel ACT- Anaheim Clinical Trials /ID# 280481AnaheimCalifornia92801-
Acpru /Id# 280382GrayslakeIllinois60030-

Find similar trials in Anaheim, CA

By research site
CenExel ACT- Anaheim Clinical Trials· Anaheim, CAAcpru· Grayslake, IL

Related Studies